O1–11–03: Anti‐malarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of NF‐κB and NLRP3 inflammasome activation
The activation of nuclear factor-kappa B (NF-κB) and NLRP3 inflammasome is involved in neuroinflammation, which is closely liked to Alzheimer's disease (AD). In vivo and in vitro studies have suggested that artemisinin show anti-inflammatory effects in inflammation-related diseases. However, the impacts of artemisinin on AD have not been investigated. In the present study, 5-month-old APPswe/PS1dE9 transgenic mice were treated daily with 40mg/Kg artemisinin for 30 days by intraperitoneal injection to evaluate the effects of artemisinin on AD. We found that artemisinin treatment (1) decreased neuritic plaque burden; (2) didn't alter Aβ transport across the blood-brain barrier; (3) regulated APP processing via inhibiting β-secretase activity; (4) inhibited NF-κB activity and NALP3 inflammasome activation in APPswe/PS1dE9 double transgenic mice.